Clinical trials: Refractory Ascites
Liver Cirrhosis, Refractory Ascites
ALFApump System Post Marketing Surveillance Registry
This is a post market surveillance registry to monitor the safety and performance of the ALFApump system.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Malignant Ascites
- Trial name
- 2011-AAR-004 (NCT01532427)
- Where
- 13 sites in Germany, Spain and 2 more
- Volunteers
- 100 people
- Sponsor
- Sequana Medical N.V.
Refractory Ascites, Children, Only
Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children
Ascites in liver cirrhosis is explained by increased production of vasoactive substances leading to renal vasoconstriction and salt and water retention.
- Trial name
- NCT04043858
- Testing
- Midodrine 2.5 mg tab
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- National Liver Institute, Egypt
Refractory Ascites in Children With Cirrhosis
Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis.
Refractory ascites is seen in 17% of cirrhotic patients with the 1year mortality rate being high, upto 20-50% [1]. The pathogenesis of cirrhotic ascites includes release of vasodilatory molecules like nitric oxide, damage…
- Trial name
- NCT05084534
- Testing
- Midodrine, Standard medical treatment
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Refractory Malignant Ascites
Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
The refractory malignant ascites is a complication of advanced stages of many cancer types. It is characterized clinically by abdominal pressure sensation, shortness of breath and pelvic pain.
- Trial name
- BEVASCITE (NCT02891369)
- Testing
- No intervention. Descriptive study
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Liver Cirrhoses, Malignant Ascites
International Alfapump Cohort Study
This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.
- Trial name
- TOPMOST (NCT04326946)
- Testing
- Alfapump
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 400 people
- Sponsor
- Sequana Medical N.V.